ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 727

Increased Risk of Coronary Artery Disease Among Patients with Class III Lupus Nephritis: A Retrospective Study of Patients at the University of North Carolina at Chapel Hill

Enid Y Sun1, Carolina Alvarez2 and Saira Z Sheikh3, 1Internal Medicine, University of North Carolina, Chapel Hill, NC, 2Thurston Arthritis Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: coronary artery disease and lupus nephritis, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk for developing coronary artery disease (CAD) compared to their cohorts without lupus. There have been several studies published that suggest that the presence of lupus nephritis (LN) is independently associated with CAD. However, none of these studies have looked at this association by class of LN. The purpose of our study was to define the characteristics of patients with SLE seen at the University of North Carolina Hospitals (UNCH); assess whether the presence of LN is independently associated with CAD; and evaluate whether this association varies according to specific LN classes.

 

Methods: A retrospective cross-sectional analysis was performed using medical records of patients 18 years and older with SLE at UNCH from April 4, 2014 to December 31, 2017. Subjects were identified using ICD-9 and ICD-10 codes specific for SLE. LN class was defined by ISN/RPS classification and determined based on review of renal biopsy and clinic notes. CAD was the outcome of interest and was defined by ICD codes for unstable angina, ST segment elevation myocardial infarction (STEMI), or non-STEMI. To determine the association between LN and CAD among SLE patients, logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI).

 

Results: The sample consisted of 3732 patients, 12% men with a mean (standard deviation) age of 48 (15.2) years; 43% White, 38% Black. Seventy percent had hypertension (HTN), 42% had dyslipidemia (DLP), 23% had diabetes mellitus (DM), and 38% had a history of smoking. Sixteen percent had LN (n=598) and 14% had CAD. When adjusting for age, sex, race/ethnicity, HTN, DLP, DM, smoking, steroid use, and disease-modifying antirheumatic drugs (DMARDs) use, the odds of having CAD were significantly higher for SLE patients with LN compared to patients without LN [OR 1.58, 95% CI (1.18, 2.14)]. In the LN analyses (Table 1), combined class III and V was significantly associated with CAD and class III alone was strongly associated with CAD. In several statistical models, class III was either strongly or significantly associated with increased risk of CAD. To better study the relationship between class III LN and CAD, all subjects with evidence of class III LN either alone or in combination were combined and the odds of CAD assessed. In this analysis any class III involvement was significantly associated with CAD compared to subjects without LN.

 

Conclusion: The results of our study confirm the findings of previous studies that LN is significantly associated with CAD after controlling for demographic, CAD, and lupus-specific factors. Ours is the first to study this association by LN class. We have shown that there may be an unexplored association between class III LN and CAD. We believe that our study reveals a critical area of further investigation and potential clinical intervention.


Disclosure: E. Y. Sun, None; C. Alvarez, None; S. Z. Sheikh, None.

To cite this abstract in AMA style:

Sun EY, Alvarez C, Sheikh SZ. Increased Risk of Coronary Artery Disease Among Patients with Class III Lupus Nephritis: A Retrospective Study of Patients at the University of North Carolina at Chapel Hill [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-coronary-artery-disease-among-patients-with-class-iii-lupus-nephritis-a-retrospective-study-of-patients-at-the-university-of-north-carolina-at-chapel-hill/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-coronary-artery-disease-among-patients-with-class-iii-lupus-nephritis-a-retrospective-study-of-patients-at-the-university-of-north-carolina-at-chapel-hill/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology